Cell therapies for joint repair/regeneration
Executive Summary
The first meeting of FDA's Cellular, Tissue & Gene Therapies Advisory Committee on March 3-4 will address cellular therapies for joint surface repair and regeneration. The panel is the former Biological Response Modifiers Advisory Committee, renamed in October by FDA to reflect more accurately its purview. The committee will also hear updates on research programs in the Center for Biologics Evaluation & Research the afternoon of March 3 and on FDA's Critical Path Initiative the morning of March 4. The meeting will be held at the Quality Suites in Rockville, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.